The FDA has approved Relistor (methylnaltrexone bromide) Subcutaneous Injection, 12 mg/0.6ml, from Salix Pharma, for the treatment of Opioid-Induced Constipation...
The FDA have provided a Complete Response Letter (CRL) following its review of a Supplemental New Drug Application (sNDA) for...
Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. announced that the FDA has accepted for review Valeant's New Drug Application...
Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc.announced the U.S. commercial launch of Relistor (methylnaltrexone bromide) Tablets, which is now...
AstraZeneca announced a co-commercialisation agreement with Daiichi Sankyo, Inc. for Movantik (naloxegol) in the USA. Under the terms of the...
Relistor is indicated for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older.
Valeant Pharmaceuticals International, Inc. and Salix Pharmaceuticals, Ltd. announced that they have entered into a definitive agreement under which Valeant...
Lantheus Holdings, Inc., parent company of Lantheus Medical Imaging, Inc. a leader in the development, manufacture and commercialization of innovative...
Shionogi has announced pivotal phase III study (COMPOSE I) results showing that once-daily treatment with S 297995 (naldemedine) significantly improved...
Shionogi announced positive results from two identically-designed 12 week phase III studies (COMPOSE I and II) demonstrating consistent efficacy and...